Literature DB >> 28596261

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Sam Bhayani, William P Bro, Sam S Chang, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Mayer Fishman, Thomas H Gallagher, John L Gore, Steven L Hancock, Michael R Harrison, Won Kim, Christos Kyriakopoulos, Chad LaGrange, Elaine T Lam, Clayton Lau, M Dror Michaelson, Thomas Olencki, Phillip M Pierorazio, Elizabeth R Plimack, Bruce G Redman, Brian Shuch, Brad Somer, Guru Sonpavde, Jeffrey Sosman, Mary Dwyer, Rashmi Kumar.   

Abstract

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts from NCCN Member Institutions consisting of medical oncologists, hematologists and hematologic oncologists, radiation oncologists, urologists, and pathologists. The NCCN Guidelines are in continuous evolution and are updated annually or sometimes more often, if new high-quality clinical data become available in the interim.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2017        PMID: 28596261     DOI: 10.6004/jnccn.2017.0100

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  156 in total

1.  Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.

Authors:  Haris Zahoor; Maria C Mir; Pedro C Barata; Andrew J Stephenson; Steven C Campbell; Amr Fergany; Robert Dreicer; Jorge A Garcia
Journal:  Invest New Drugs       Date:  2019-06-24       Impact factor: 3.850

2.  [Evaluating inferior vena cava wall invasion in renal cell carcinoma tumor thrombus with MRI].

Authors:  J Y Wu; Y Mi; S Liu; L Yao; Q Tang; Z S He; X Y Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

3.  18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.

Authors:  Akira Toriihara; Heying Duan; Holly M Thompson; Sonya Park; Negin Hatami; Lucia Baratto; Alice C Fan; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-08       Impact factor: 9.236

4.  Pathologic T3a renal cell carcinoma: a classification in need of further refinement.

Authors:  John M DiBianco; Patrick T Gomella; Mark W Ball
Journal:  Ann Transl Med       Date:  2018-12

5.  Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma.

Authors:  Francesco A Mistretta; Elio Mazzone; Sophie Knipper; Pierre I Karakiewicz
Journal:  Ann Transl Med       Date:  2018-12

6.  Bilateral renal cell carcinoma with bilateral adrenal metastasis: a therapeutic challenge.

Authors:  Tanica Pandey; Siddharth Pandey; Vishwajeet Singh; Ashish Sharma
Journal:  BMJ Case Rep       Date:  2018-12-13

7.  Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Toshio Takagi; Hidekazu Tachibana; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Hirohito Kobayashi; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 8.  Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Authors:  Nieves Martinez Chanza; Abhishek Tripathi; Lauren C Harshman
Journal:  Curr Treat Options Oncol       Date:  2019-05-03

9.  Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model.

Authors:  Xi Chen; Zhiguo Zhou; Raquibul Hannan; Kimberly Thomas; Ivan Pedrosa; Payal Kapur; James Brugarolas; Xuanqin Mou; Jing Wang
Journal:  Phys Med Biol       Date:  2018-10-24       Impact factor: 3.609

10.  A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma.

Authors:  Michio Kimura; Eiseki Usami; Hitomi Teramachi; Tomoaki Yoshimura
Journal:  Mol Clin Oncol       Date:  2020-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.